PharmaPoint: Painful Diabetic Neuropathy-Global Drug Forecast and Market Analysis to 2026

Orbisresearch.com published “Painful Diabetic Neuropathy Market” from its database. The report provides an extensive research and detailed analysis of the present market along with future outlook. The report Overview of PDN, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Dallas, United States – May 2, 2018 /MarketersMedia/ —

PharmaPoint: Painful Diabetic Neuropathy Market 2018-2026:
Painful diabetic neuropathy is a late-stage complication that occurs in patients suffering from diabetes mellitus and is thought to affect up to half of patients with the disease. PDN manifests itself as a variety of syndromes which differ in clinical course, distribution, fibre involvement and, pathophysiology. Symptoms will vary from patient to patient however; the most common pain symptoms are reported to be numbness, tingling, burning, sharp, and dull/ache-like, which are often localized to the extremities, affecting the feet and hands.

Currently, there are only three approved therapies for the treatment of PDN, Pfizer’s Lyrica, Eli Lilly’s Cymbalta, and Grünenthal’s Nucynta ER. Acorda Therapeutics has marketed an 8% capsaicin patch (Qutenza) which is approved for peripheral neuropathic pain and may be used in certain PDN syndromes. Outside of these drugs the market consists of off label use and generics.

GlobalData estimates that drug sales for PDN in 2016 were approximately $3.1B across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $7.1B at a CAGR of 8.7%. This growth will be driven by the launch of four late-stage pipeline products. The two highest selling drugs are expected to be ViroMed’s VM202 and Daiichi-Sankyo’s mirogabalin besylate, which both address some of the unmet needs in the market.

Request a Sample PDF of this Report@ http://orbisresearch.com/contacts/request-sample/2123717

Scope:

– Overview of PDN, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
– Annualized PDN therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (typical and atypical) forecast from 2016 to 2026.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PDN therapeutics market
– Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PDN therapy. The most promising candidates in Phase III development are profiled.
– Analysis of the current and future market competition in the global PDN therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy:

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global PDN therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PDN therapeutics market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Have any query? Feel free to ask us@ http://orbisresearch.com/contacts/enquiry-before-buying/2123717

Companies Mentioned:

– Pfizer
– Grunethal
– Daiichi-Sankyo
– Depomed
– ViroMed

Some Points from TOC:

1 Table of Contents
2 Painful Diabetic Neuropathy: Executive Summary
3 Introduction
4 Disease Overview
5 Epidemiology
6 Disease Management
7 Competitive Assessment
8 Unmet Needs and Opportunity Assessment
9 Pipeline Assessment
10 Current and Future Players
11 Market Outlook

Are you looking for a DISCOUNT before purchasing this report? If yes, contact us@ http://orbisresearch.com/contacts/discount/2123717 &

Get more access with full TOC@ http://orbisresearch.com/reports/index/pharmapoint-painful-diabetic-neuropathy-global-drug-forecast-and-market-analysis-to-2026

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Info:
Name: Hector Costello
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A.
Phone: +1 (214) 884-6817

Source URL: https://marketersmedia.com/pharmapoint-painful-diabetic-neuropathy-global-drug-forecast-and-market-analysis-to-2026/339746

For more information, please visit http://www.orbisresearch.com

Source: MarketersMedia

Release ID: 339746